ClinicalTrials.gg
Active, not recruitingNCT05522361RISEUpdated Feb 7, 2024

Risdiplam in Patients With Spinal Muscular Atrophy Previously Treated With Nusinersen

A Phase 4 interventional study of Risdiplam in Spinal Muscular Atrophy, sponsored by Clinic for Special Children. Active, not recruiting at 1 site in United States. Open to participants aged 2 Years to 35 Years. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Clinic for Special Children · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
2 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing risdiplam in Muscular Atrophy, Spinal — none open to participants now, 4 under way, none of them phase 3. Risdiplam · Muscular Atrophy, Spinal.

Planned enrollment
13th of 13
10 · median 33
Started
2022
with 1 other
Phase 4
4 of 13
none open now
Registered
10th of 13
by date
Lead sponsor
1 of 13
Clinic for Special Children

Among the 13 studies testing risdiplam in Muscular Atrophy, Spinal, this one is the 13th largest by planned enrollment, is one of 2 that started in 2022, is one of 4 in phase 4, and was the 10th registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

None of the 13 studies testing risdiplam in Muscular Atrophy, Spinal is open now. The open studies under Muscular Atrophy, Spinal, anywhere →

About risdiplam

Risdiplam: first FDA approval 2020 (EVRYSDI), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing risdiplam in Muscular Atrophy, Spinal as a file.
02

Study summary

Risdiplam Exchange (RISE) is a study of spinal muscular atrophy (SMA) patients who crossover to 36 months of open-label risdiplam monotherapy following a comparable period of nusinersen treatment. The schedule of assessments (SOAs) carry over seamlessly for the cohort from studies done while treated with nusinersen and continue to track the most informative outcomes from that trial (e.g. nine hole peg test and grip strength), while adding the Box and Block Test (BBT) as an additional measure of upper limb endurance and function.

Read the detailed description

Risdiplam is an orally bioavailable small molecule that distributes into the central nervous system (CNS) and peripheral tissues where it modifies SMN2 pre-mRNA splicing and increases tissue SMN protein levels. It was approved by the U.S. Food and Drug Administration for all SMA patients older than 2 months of age in August 2020.

Clinical trial data prompted us to consider risdiplam a reasonable alternative to nusinersen administered intrathecally or by subcutaneous intrathecal catheter (SIC) for patients with more advanced SMA. Considered within this clinical context, risdiplam presents a significant advantage by eliminating the risks of mechanical failure, intrathecal bleeding, and CNS infection associated with the SIC device. The schedule of assessments (SOAs) used in this cohort during the previous three-year period as part of a nusinersen study provide us with an established framework for data collection. Thus, the overall clinical experience with risdiplam as compared to nusinersen can be assessed using a prospective, crossover design in a real-world setting.

03

Conditions studied

  • Spinal Muscular Atrophy

Keywords

  • nusinersen
  • prospective
  • risdiplam
04

Who can participate

Ages eligible
2 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Biallelic SMN1 deletions
  • 3 or 4 copies of SMN2
  • Prior treatment with nusinersen for a minimum of 22 months

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with SMN gene replacement therapy
  • Prior exposure to another agent.
  • Confounding neuromuscular disorder other than SMA
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Open-label crossover

    Participants crossover to 36 months of open-label risdiplam mono therapy following a comparable period of nusinersen treatment.

    Drug: Risdiplam

Interventions

  • administered to participants per product label insert

06

What researchers measure

Primary outcomes

  1. Comparative intrasubject performance on nine hole peg test (NHPT)

    Time in seconds to place and subsequently remove nine one inch pegs in holes assessed in dominant and non dominant hands

    Time frame: 36 months

Secondary outcomes

  1. Intrasubject changes in lower limb and overall motor function

    Revised Hammersmith Scale (RHS) of 33 items with grades of 0 (unable),1 (attempted, not completed) and 2 (achieves task); the greater the sum total, the higher overall motor function.

    Time frame: 36 months

  2. Intrasubject changes in upper limb motor function

    box and block test (BBT): number of 1 inch wood blocks moved from one compartment to an adjacent one over a wall within 5 minutes, with more blocks moved corresponding to higher upper limb motor function

    Time frame: 36 months

  3. Intrasubject change in pulmonary function

    maximal inspiratory pressure (MIP) and mean expiratory pressure (MEP), measured in centimeters of water displaced

    Time frame: 36 months

  4. Frequency and type of adverse events

    laboratory testing, self-reported, and observed during the study

    Time frame: 36 months

  5. Comparative intrasubject change in grip strength

    hand-held dynamometry (MyoGrip and MyoPinch) measures force in Newtons

    Time frame: 36 months

07

Study locations

1 site
08

References and documents

Publications

  • Strauss KA, Carson VJ, Brigatti KW, Young M, Robinson DL, Hendrickson C, Fox MD, Reed RM, Puffenberger EG, Mackenzie W, Miller F. Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy. J Pediatr Orthop. 2018 Nov/Dec;38(10):e610-e617. doi: 10.1097/BPO.0000000000001247. PubMed 30134351 ↗
  • Carson VJ, Young M, Brigatti KW, Robinson DL, Reed RM, Sohn J, Petrillo M, Farwell W, Miller F, Strauss KA. Nusinersen by subcutaneous intrathecal catheter for symptomatic spinal muscular atrophy patients with complex spine anatomy. Muscle Nerve. 2022 Jan;65(1):51-59. doi: 10.1002/mus.27425. Epub 2021 Oct 19. PubMed 34606118 ↗
  • Ribero VA, Daigl M, Marti Y, Gorni K, Evans R, Scott DA, Mahajan A, Abrams KR, Hawkins N. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. J Comp Eff Res. 2022 Apr;11(5):347-370. doi: 10.2217/cer-2021-0216. Epub 2022 Jan 18. PubMed 35040693 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Dec 2025, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2022
First posted
Aug 31, 2022
StartActual
Nov 6, 2022
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jun 15, 2026
Last update
Feb 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05522361
Lead sponsor
Clinic for Special Children
Collaborators
Genentech, Inc.
Responsible party
Kevin A. Strauss, MD (Medical Director, Clinic for Special Children) — Principal investigator
First posted
Aug 31, 2022
Start date
Nov 6, 2022
Primary completion
Dec 31, 2025 (estimated)
Completion
Jun 15, 2026 (estimated)
Last update
Feb 7, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risdiplam

Start the discussion